Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 1.00 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599333 | 0.84 | HCAR2 (0.72) | HCAR2HCAR3DAO | |
| SCHEMBL9014909 | 0.82 | HCAR2 (0.69) | HCAR2HCAR3DAO | |
| SCHEMBL18295108 | 0.82 | HCAR2 (0.69) | HCAR2HCAR3DAO | |
| SCHEMBL3954952 | 0.82 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL7372956 | 0.82 | HCAR2 (0.69) | HCAR2HCAR3DAO | |
| SCHEMBL5600095 | 0.81 | HCAR2 (0.73) | HCAR2HCAR3DAO | |
| SCHEMBL3999370 | 0.79 | HCAR2 (1.00) | HCAR2HCAR3DAO | |
| SCHEMBL5600058 | 0.79 | HCAR2 (0.65) | HCAR2HCAR3DAO | |
| SCHEMBL5599811 | 0.79 | HCAR2 (0.69) | HCAR2HCAR3DAO | |
| SCHEMBL5599509 | 0.79 | HCAR2 (1.00) | HCAR2HCAR3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | claimed |
| EP-4611820-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | ALX Oncology Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250101032-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | ALX Oncology Inc. | 2025-03-27 | — | — | US | disclosed |
| CN-115515681-B | GPR52 modulator compounds | 奈克斯拉制药英国有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118251395-A | Esatitecan derivatives and antibody-drug conjugates thereof | ALX肿瘤学股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024098066-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | ALX Oncology Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4334322-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | ALX Oncology Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-115515681-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022236136-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | ALX Oncology Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1633351-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005011677-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6600071-B2 | Starting materials or intermediates and the cyclization of these under suitable reaction conditions to give compounds of the formula I. The intermediates of the formula II are novel. for argrochemicals | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | HCAR2 52/4885HCAR3 150/4885DAO 2261/4885 |
| US-20250101032-A1 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | CTSB, CTSE, CTSD | HCAR2 1493/4885HCAR3 988/4885DAO 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.